Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Accounts Payables (2016 - 2025)

Dexcom (DXCM) has disclosed Accounts Payables for 15 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 22.64% to $1.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 22.64% increase, with the full-year FY2025 number at $1.9 billion, up 22.64% from a year prior.
  • Accounts Payables was $1.9 billion for Q4 2025 at Dexcom, up from $1.6 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.9 billion in Q4 2025 to a low of $573.0 million in Q4 2021.
  • A 4-year average of $1.4 billion and a median of $1.5 billion in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: grew 17.81% in 2024, then grew 22.64% in 2025.
  • Dexcom's Accounts Payables stood at $573.0 million in 2021, then soared by 134.82% to $1.3 billion in 2023, then increased by 17.81% to $1.6 billion in 2024, then increased by 22.64% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Accounts Payables are $1.9 billion (Q4 2025), $1.6 billion (Q4 2024), and $1.3 billion (Q4 2023).